Home » Stocks » Corcept Therapeutics

Corcept Therapeutics Incorporated (CORT)

Stock Price: $14.80 USD -0.16 (-1.04%)
Updated Aug 3, 2020 10:31 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.70B
Revenue (ttm) 334.90M
Net Income (ttm) 105.97M
Shares Out 114.60M
EPS (ttm) 0.87
PE Ratio 17.01
Forward PE 16.92
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $14.80
Previous Close $14.95
Change ($) -0.16
Change (%) -1.04%
Day's Open 15.06
Day's Range 14.52 - 15.06
Day's Volume 280,593
52-Week Range 9.70 - 18.53

More Stats

Market Cap 1.70B
Enterprise Value 1.39B
Earnings Date (est) Aug 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 114.60M
Float 94.86M
EPS (basic) 0.92
EPS (diluted) 0.87
FCF / Share 1.26
Dividend n/a
Dividend Yield n/a
Earnings Yield 5.88%
FCF Yield 8.54%
Payout Ratio n/a
Shares Short 22.65M
Short Ratio 21.40
Short % of Float 25.61%
Beta 1.14
PE Ratio 17.01
Forward PE 16.92
P/FCF Ratio 11.71
PS Ratio 5.06
PB Ratio 4.50
Revenue 334.90M
Operating Income 130.36M
Net Income 105.97M
Free Cash Flow 144.83M
Net Cash 304.20M
Net Cash / Share 2.65
Gross Margin 89.87%
Operating Margin 38.93%
Profit Margin 31.60%
FCF Margin 43.25%
ROA 21.28%
ROE 30.49%
ROIC 43.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 0
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$16.75*
(13.21% upside)
Low
7.00
Current: $14.80
High
26.00
Target: 16.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue30625115981.3250.2926.5510.363.31--
Revenue Growth21.99%57.82%95.77%61.72%89.39%156.36%213.18%---
Gross Profit30124615679.2648.9325.6710.213.22--
Operating Income11289.5052.8610.18-3.44-27.62-41.50-36.27-32.33-27.44
Net Income94.1875.411298.14-6.41-31.38-46.01-38.05-32.35-25.97
Shares Outstanding11411511411110710199.8293.0283.3168.34
Earnings Per Share0.770.601.040.07-0.06-0.31-0.46-0.41-0.39-0.38
EPS Growth28.33%-42.31%1385.71%-------
Operating Cash Flow13611660.9418.393.13-27.38-37.06-36.02-27.40-22.29
Capital Expenditures-1.09-0.30-0.42-0.19-0.02-0.17-0.13-0.15-0.03-
Free Cash Flow13511560.5218.203.11-27.55-37.19-36.17-27.43-22.29
Cash & Equivalents27620788.7451.5440.4424.2554.8893.0339.6424.58
Total Debt3.46--14.6627.4933.8935.0731.68--
Net Cash / Debt27320788.7436.8712.94-9.6419.8161.3539.6424.58
Assets41231222168.7551.9034.6363.0899.1739.8325.10
Liabilities41.1335.8129.5727.3733.4038.0242.0637.395.033.86
Book Value37127619141.3818.50-3.3921.0261.7834.8121.24
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Corcept Therapeutics Incorporated
Country United States
Employees 206
CEO Joseph K. Belanoff

Stock Information

Ticker Symbol CORT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CORT

Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator that is in Phase II for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.